NEW YORK (GenomeWeb) – Fluidigm today announced it has signed a deal to distribute and co-market GenomOncology's GO Clinical Workbench software for variant interpretation.

Under the terms of the agreement, Fluidigm will offer the software solution to customers for the interpretation of somatic variants identified using Fluidigm's Juno targeted next-generation sequencing library preparation systems.

GO Clinical Workbench is built on a curated database that provides information on variants related to driver mutations, pharmacogenomics, prognosis, and cell-signaling pathways.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.